SCHEMBL4772377

SCHEMBL4772377

CS(=O)(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(CN)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 1/20 0.47
LMNA P02545 3/20 0.44
POLB P06746 2/20 0.44
GAA P10253 1/20 0.43
ALDH1A1 P00352 2/20 0.41
TAAR1 Q96RJ0 1/20 0.41
RECQL P46063 1/20 0.40
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 1/20 0.37
KDM4E B2RXH2 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
IDO1 P14902 1/20 0.36
CSNK2A2 P19784 1/20 0.36
CSNK2B P67870 1/20 0.36
CSNK2A1 P68400 1/20 0.36
CSNK2A3 Q8NEV1 1/20 0.36
PTPN1 P18031 1/20 0.36
PTPN6 P29350 1/20 0.36
PTPN11 Q06124 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777644 0.88 GAA (0.45) LMNAPOLBGAAALDH1A1RECQL
SCHEMBL4771201 0.87 LMNA (0.50) PNMTLMNAPOLBGAAALDH1A1
SCHEMBL4777553 0.86 ALDH1A1 (0.49) LMNAPOLBGAAALDH1A1RECQL
SCHEMBL4776528 0.86 GAA (0.62) LMNAPOLBGAAALDH1A1RECQL
SCHEMBL4775349 0.86 LMNA (0.41) LMNAPOLBGAAALDH1A1RECQL
SCHEMBL4773540 0.84 GAA (0.43) LMNAPOLBGAAALDH1A1RECQL
SCHEMBL4769594 0.83 GAA (0.48) LMNAPOLBGAAALDH1A1RECQL
SCHEMBL4777413 0.83 KDM4E (0.52) LMNAPOLBGAAALDH1A1MEN1
SCHEMBL4769629 0.82 GAA (0.52) LMNAPOLBGAAALDH1A1MEN1
SCHEMBL4773076 0.82 PER2 (0.43) LMNAPOLBGAAALDH1A1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 PNMT 2916/4885LMNA 1022/4885POLB 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.